livestock drive stock
deliv anoth impress oper perform provid
outlook exceed street expect manag guid
revenu midpoint adj ep
midpoint sale livestock segment came
vs estim us livestock segment driven increas
sale premium product favor weather importantli livestock
busi annual implement veterinarian feed direct
neg affect result overal
sale companion health continu driven lead dermatolog asset
apoquel cytopoint antiparasit simparica combin sale
apoquel cytopoint came manag guid sale
least see achiev consid signific
opportun expand intern apoquel yet avail china
cytopoint introduc eu market late said derm
franchis powerhous need replenish companion
pipelin sinc appear legaci portfolio face headwind gener well
brand competit notabl rimidyl elanco/aratana gallipr
manag highlight diagnost offer avenu growth see
diagnost segment abl leverag exist relationship
clinic also increas sale complementari product provid bundl
discount custom
increas adj ep estim revenu
continu perform well market expand
share key intern geographi valuat price-to-earnings keep us sidelin
maintain equal weight rate increas price target
new pt base ep prior pt base
prior estim
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
appear fairli valu view
fundament appear intact oper effici
gain larg complet put pressur
sustain top-lin growth apoquel simparica
cytopoint repres attract asset
obviou much extend recent
string pearl
upsid case assum strong recoveri
global anim health market next two year
per year zoeti achiev gm
expans longer term factor
drive upsid case ep
downsid case assum stagnat
anim health market lower uptak
derm product growth pace
soft industri outlook gm improv
longer term factor lead
downsid ep
dougla tsao herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
